Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (8165)	1/2/1999 8:15:00 AM
From: Robert K.	Respond to of 17367

From>clinical progress>note the wording.>>>>>>>>>>>>>>>>>>>>>> >>>We plan to take at least one additional NEUPREX® medical indication into the clinic within the next few months.<< Why not just say "one" indication? I do believe they have multiple choices. The wording "at least one" indicates that they are thinking about "more than" one. IMO it depends more on the circumstances of clinicals/money/collaborations etc. I still think its a gutsy thought based on their "current" money level. The idea that they are even thinking this makes me wonder. This leads me to believe that perhaps they have a different handle on clinicals/money/collaborations than we do. Just my guesswork. Last thought, back in 95 they started 3 indications within 2 months or so. They added a fourth (i think) 6 months after that. It can be done. All IMO. All disclaimers always. Consider nothing as fact.